Falcon Point Capital LLC trimmed its stake in shares of Aclaris Therapeutics Inc (NASDAQ:ACRS) by 44.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 9,908 shares of the biotechnology company’s stock after selling 7,883 shares during the quarter. Falcon Point Capital LLC’s holdings in Aclaris Therapeutics were worth $244,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. Citigroup Inc. raised its position in shares of Aclaris Therapeutics by 171.8% during the 2nd quarter. Citigroup Inc. now owns 4,313 shares of the biotechnology company’s stock worth $117,000 after purchasing an additional 2,726 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in shares of Aclaris Therapeutics during the 3rd quarter worth approximately $142,000. Teacher Retirement System of Texas acquired a new stake in shares of Aclaris Therapeutics during the 4th quarter worth approximately $200,000. Voya Investment Management LLC acquired a new stake in shares of Aclaris Therapeutics during the 2nd quarter worth approximately $247,000. Finally, PNC Financial Services Group Inc. raised its position in shares of Aclaris Therapeutics by 26.0% during the 2nd quarter. PNC Financial Services Group Inc. now owns 9,220 shares of the biotechnology company’s stock worth $250,000 after purchasing an additional 1,900 shares during the period. Institutional investors and hedge funds own 92.47% of the company’s stock.

A number of equities analysts recently issued reports on ACRS shares. BidaskClub lowered Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, December 20th. Cantor Fitzgerald set a $50.00 price objective on Aclaris Therapeutics and gave the stock a “buy” rating in a report on Friday, December 15th. Guggenheim started coverage on Aclaris Therapeutics in a report on Thursday, February 8th. They issued a “buy” rating and a $53.00 price objective for the company. Finally, Zacks Investment Research lowered Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. Three equities research analysts have rated the stock with a sell rating and four have issued a buy rating to the stock. Aclaris Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $41.80.

Aclaris Therapeutics Inc (NASDAQ ACRS) opened at $19.48 on Wednesday. Aclaris Therapeutics Inc has a fifty-two week low of $18.46 and a fifty-two week high of $33.25.

COPYRIGHT VIOLATION NOTICE: “Falcon Point Capital LLC Reduces Stake in Aclaris Therapeutics Inc (ACRS)” was first reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://theolympiareport.com/2018/02/14/falcon-point-capital-llc-reduces-stake-in-aclaris-therapeutics-inc-acrs.html.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Want to see what other hedge funds are holding ACRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aclaris Therapeutics Inc (NASDAQ:ACRS).

Institutional Ownership by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.